Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
The company will also share results in two additional posters for deuruxolitinib
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Subscribe To Our Newsletter & Stay Updated